EP
MCRB icon

Eversept Partners’s Seres Therapeutics MCRB Stock Holding History

Eversept Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,910
Closed -$303K – 74
2024
Q2 		$303K Sell
20,910
-48,537
-70% -$810K 0.02% 74
2024
Q1 		$1.08M Sell
69,447
-18,230
-21% -$393K 0.07% 67
2023
Q4 		$2.45M Sell
87,677
-29,951
-25% -$786K 0.22% 48
2023
Q3 		$5.6M Sell
117,628
-36,210
-24% -$2.76M 0.47% 38
2023
Q2 		$14.7M Buy
153,838
+27,005
+21% +$2.94M 1.23% 21
2023
Q1 		$14.4M Buy
126,833
+16,783
+15% +$1.82M 1% 21
2022
Q4 		$12.3M Buy
110,050
+13,259
+14% +$1.78M 1.08% 22
2022
Q3 		$12.4M Buy
+96,791
New +$9.91M 1.08% 23
2021
Q3 		– Sell
-2,978
Closed -$1.42M – 115
2021
Q2 		$1.42M Sell
2,978
-7,786
-72% -$3.29M 0.09% 72
2021
Q1 		$4.43M Sell
10,764
-5,938
-36% -$2.73M 0.33% 50
2020
Q4 		$8.18M Buy
+16,702
New +$9.78M 0.96% 30

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Eversept Partners's MCRB Position: Q3 2024 in Review

Eversept Partners sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 20,910 shares — an estimated $303K sold.

Eversept Partners first reported a position in MCRB in Q4 2020 and held it in 11 quarters. The position peaked at $14.7M in Q2 2023. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

  • Eversept Partners reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Eversept Partners sold 20,910 Seres Therapeutics shares in Q3 2024, an estimated $303K.
  • Eversept Partners first reported a position in Seres Therapeutics in Q4 2020 and held it in 11 quarters.
  • Eversept Partners's Seres Therapeutics position peaked at $14.7M in Q2 2023.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.